Terry Hammond, MD
Nephrology · American Fork, UTNPI 1124064845
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $333 of the $399 with a category attached, or 83.4%. 12 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 25.2% of the total. Reporting peaked in 2024 at $160 and has fallen 66.6% since, to $53 in 2025. That places this record below the midpoint for nephrology clinicians in UT, where the typical reported total is $1,171.
Across 24 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$101
- Baxter Healthcare$57
- Genentech, Inc.$53
- Ardelyx, Inc.$42
- Aurinia Pharma U.S., Inc.$28
- Vifor Pharma, Inc.$21
- plus $96 from 6 others
What the payments were for
- Food & beverage$33383%
- Education$6617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Baxter Healthcare | 1 | $57 |
| Genentech, Inc. | 1 | $53 |
| Ardelyx, Inc. | 2 | $42 |
| Aurinia Pharma U.S., Inc. | 2 | $28 |
| Vifor Pharma, Inc. | 1 | $21 |
| Calliditas Therapeutics US Inc. | 1 | $21 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Strongbridge US Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Bayer | 1 | $14 |
| Travere Therapeutics, Inc. | 7 | $13 |
How this compares
$399 in reported general payments places this provider in the 35th percentile of 74 nephrology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 15 | $4,620 |
| Potassium Citrate ErPotassium Citrate | 22 | $2,306 |
| Carvedilol | 96 | $1,492 |
| Hydralazine Hcl | 34 | $695 |
| Amlodipine Besylate | 79 | $631 |
| Losartan Potassium | 47 | $626 |
| Lisinopril | 63 | $586 |
| Calcitriol | 35 | $463 |
| Prednisone | 35 | $433 |
| Midodrine Hcl | 15 | $391 |
| Furosemide | 65 | $313 |
| Potassium Chloride | 15 | $256 |
| Omeprazole | 11 | $248 |
| Olmesartan Medoxomil | 31 | $201 |
| Allopurinol | 20 | $194 |
Paid to pharmacies, not to this prescriber.
Other nephrology in American Fork
- Zachary FreestoneAmerican Fork$1K
- Sanjiv AnandSouth Salt Lake$144K
- Alfred CheungSalt Lake City$132K
- Donald KohanSalt Lake City$119K
- Anitha VijayanMurray$118K
- Fuad ShihabSalt Lake City$83K
- William BaragerProvo$13K
- Srinivasa BeddhuSalt Lake City$8K
- George JaradSaint George$7K
- Carlos MercadoSt George$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.